You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

73 Results
Guidelines and Advice
Jul 2017
Guidelines and Advice
Jul 2017
Guidelines and Advice
Status: Current
ID: GL 4-1
Version: 2
Jan 2021
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Guidelines and Advice
Status: Archived
ID: 2-14
Version: 3
Apr 2011
Guidelines and Advice
Status: Archived
ID: 1-4
Sep 2012
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Symptom Management
Symptom Management
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages